Novartis AG ADR (NVS)vsInsulet Corporation (PODD)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
PODD
Insulet Corporation
$172.14
+7.57%
HEALTHCARE · Cap: $11.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1989% more annual revenue ($56.58B vs $2.71B). NVS leads profitability with a 23.9% profit margin vs 9.1%. PODD appears more attractively valued with a PEG of 1.01. PODD earns a higher WallStSmart Score of 59/100 (C).
NVS
Buy51
out of 100
Grade: C-
PODD
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
-49.6%
Fair Value
$167.73
Current Price
$172.14
$4.41 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Revenue surging 31.2% year-over-year
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
3.9% earnings growth
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : PODD
The strongest argument for PODD centers on Revenue Growth. Revenue growth of 31.2% demonstrates continued momentum. PEG of 1.01 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : PODD
The primary concerns for PODD are EPS Growth, P/E Ratio. A P/E of 46.1x leaves little room for execution misses.
Key Dynamics to Monitor
NVS profiles as a declining stock while PODD is a hypergrowth play — different risk/reward profiles.
PODD carries more volatility with a beta of 1.47 — expect wider price swings.
PODD is growing revenue faster at 31.2% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
PODD scores higher overall (59/100 vs 51/100) and 31.2% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Insulet Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?